Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SAT1 | P21673 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038043 | 0.97 | — | — | |
| SCHEMBL5802301 | 0.90 | KDM1A (0.62) | KDM1ACYP2C19MEN1GLAKMT2A | |
| SCHEMBL5611699 | 0.86 | ADRB2 (0.34) | KDM1ATSHRTP53ADRB2ADRB1 | |
| SCHEMBL5611639 | 0.86 | ADRB2 (0.34) | KDM1ATSHRTP53ADRB2ADRB1 | |
| SCHEMBL22756216 | 0.85 | KDM1A (0.67) | KDM1ACYP2C19MEN1GLAKMT2A | |
| SCHEMBL21216247 | 0.84 | ADH1B (0.36) | KDM1ATSHRADRB2ADRB1 | |
| SCHEMBL31294 | 0.83 | — | — | |
| SCHEMBL368094 | 0.83 | ADRB2 (0.35) | TSHRADRB2ADRB1 | |
| SCHEMBL8637555 | 0.81 | KDM1A (0.78) | KDM1ACYP2C19MEN1GLAKMT2A | |
| SCHEMBL8637561 | 0.81 | KDM1A (0.78) | KDM1ACYP2C19MEN1GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934380-B1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | TRICIDA, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054669-A1 | COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | TRICIDA, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934380-B1 | Crosslinked poly(allylamine) polymer pharmaceutical compositions | PARG, PARN, AAAS | KDM1A 2777/4885CYP2C19 316/4885MEN1 1766/4885 |
| US-20200054669-A1 | COMPOSITIONS FOR AND METHODS OF TREATING ACID-BASE DISORDERS | SLC10A2, SLC10A1, SLC26A3 | KDM1A 4485/4885CYP2C19 525/4885MEN1 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.